Search results
Showing 76 to 90 of 1002 results for public health medicine & health
In development Reference number: GID-TA11956 Expected publication date: 28 January 2027
Awaiting development Reference number: GID-TA11978 Expected publication date: TBC
This guideline covers how to create the right conditions for mental wellbeing at work. It aims to promote a supportive and inclusive work environment, including training and support for managers and helping people who have or are at risk of poor mental health.
This quality standard covers ways to reduce suicide and help people bereaved or affected by suicide. It describes high-quality care in priority areas for improvement.
View quality statements for QS189Show all sections
Sections for QS189
- Quality statements
- Quality statement 1: Multi-agency suicide prevention partnerships
- Quality statement 2: Reducing access to methods of suicide
- Quality statement 3: Media reporting
- Quality statement 4: Involving family, carers or friends
- Quality statement 5: Supporting people bereaved or affected by a suspected suicide
- Update information
- About this quality standard
In development Reference number: GID-TA11996 Expected publication date: 13 May 2027
In development Reference number: GID-TA11809 Expected publication date: 03 June 2027
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 30 June 2026.
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]
In development Reference number: GID-TA11414 Expected publication date: TBC
In development Reference number: GID-TA11566 Expected publication date: TBC
Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446]
In development Reference number: GID-TA11552 Expected publication date: 09 September 2026
Bepirovirsen with nucleoside or nucleotide analogues for treating chronic hepatitis B [ID6608]
In development Reference number: GID-TA11803 Expected publication date: 10 March 2027
Norucholic acid for treating primary sclerosing cholangitis [ID6583]
Awaiting development Reference number: GID-TA11782 Expected publication date: 29 April 2027
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]
In development Reference number: GID-TA11116 Expected publication date: 11 November 2026
This guideline covers how to improve the health and wellbeing of employees, with a focus on organisational culture and the role of line managers.
In development Reference number: GID-TA11221 Expected publication date: TBC